Age-related macular degeneration Eye Diseases
Conditions
Interventions
Current interventions as of 06/04/2021:
All patients will be randomly assigned to use one of two treatments (Dose A: Viscofresh 10mg/ml or Dose B: Systane Ultra Plus Hydration). Befor
Sponsors
Oftalmología Vistahermosa SL
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 06/04/2021: 1. Patients with anti-vascular endothelial growth treatment with Lucentis 10mg/ml (ranibizumab, Novartis) for age-related macular degeneration 2. Patients must have already received a minimum of three injections of this treatment 3. Age between 51 and 90 years _____ Previous inclusion criteria: 1. Patients with anti-vascular endothelial growth treatment with Lucentis 10mg/ml (ranibizumab, Novartis) for age-related macular degeneration 2. Patients must have already received a minimum of three injections of this treatment 3. Age between 50 and 90 years
Exclusion criteria
Exclusion criteria: 1. Glaucoma 2. Dry eye 3. Previous refractive surgery or recent cataract surgery (less than 6 months)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ocular Surface Discomfort Index questionnaire measured at baseline, 7, 30, 37 and 60 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline, 7, 30, 37 and 60 days: 1. Meniscus tear height measured using Keratograph device 2. Conjunctival hyperemia measured using Keratograph device 3. Non-invasive keratographic tear film break-up time (BUT) measured using Keratograph device 4. Dry eye symptoms measured using the DEQ-5 questionnaire 5. Corneal staining measured using Keratograph device 6. Fluorescein BUT measured using Keratograph device 7. Meibomiography measured using Keratograph devie | — |
Countries
Spain
Outcome results
None listed